Four of the MET variants we observed have also been reported in TCGA apparently sporadic cancers (p.M362T, p.S572N, p.R988C, and p.T992I) but with a notably lower overall frequency compared to our patient series (10 of 87 or 11.5% in CS/CS-like/BRRS versus 99 of 3476 or 2.8% in TCGA; OR = 4.43, 95% CI 2.11–8.56, p = 0.00032). This evidence concerns the gene MET and cancer.